Hematological Neoplasms
In recent years, with the application of new treatment methods, the early mortality rate of multiple myeloma patients has been significantly reduced, and the prognosis of multiple myeloma patients has been improved. Early identification of multiple myeloma and precise risk stratification are crucial for treatment.
As of April 2024, the FDA has approved two CAR-T cell therapies for the treatment of multiple myeloma, Abecma (Idecabtagene vicleucel) and Carvykti (Ciltacabtagene Autoleucel, cilta-cel). Here is a brief introduction to these two CAR-T cell therapies.
On March 1, 2024, blood tumor patients welcomed another encouraging piece of news. China’s National Medical Products Administration (NMPA) officially issued a notification approving the New Drug Application (NDA) for Zevorcabtagene Autoleucel (CT053) injection, developed by Keymed Biosciences, for the treatment of relapsed or refractory multiple myeloma (approval date: February 23, 2024).
Equecabtagene Autoleucel injection (IASO Bio development code: CT103A; Innovent Biologics development code: IBI326) is an innovative CAR-T product targeting BCMA. In February 2023, the FDA granted this drug Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of relapsed/refractory multiple myeloma.
Carvykti® (cilta-cel, Ciltacabtagene Autoleucel) is the first CAR-T cell therapy to receive a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the second-line treatment of patients with relapsed or refractory multiple myeloma.
Bluebird bio, a pioneering biotechnology company, in collaboration with Bristol Myers Squibb, has developed a groundbreaking treatment called Abecma, a chimeric antigen receptor (CAR) T-cell therapy that harnesses the power of the body’s immune system to combat this aggressive disease.
Abecma is a groundbreaking form of cellular immunotherapy known as chimeric antigen receptor (CAR) T-cell therapy. This cutting-edge treatment involves extracting a patient’s own T-cells (a type of immune cell) and genetically modifying them in a laboratory to recognize and attack cancer cells.
On April 9, 2024, the U.S. Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for the treatment of triple-exposed relapsed or refractory multiple myeloma.
To date, four BCMA CAR-T products have been approved globally for the treatment of adult relapsed or refractory multiple myeloma (RRMM), but there have been no head-to-head studies comparing the efficacy of these products.